SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased ...
Gossamer Bio’s updated model now points to a fair value of $95.40, up from $82.48, which marks a meaningful shift in the ...
The MarketWatch News Department was not involved in the creation of this content. - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week ...
The average one-year price target for Gossamer Bio (NASDAQGS:GOSS) has been revised to $80.05 / share, representing a 40.76% decrease from the prior estimate of $135.13 dated September 11, 2026. This ...
Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a ...
View source version on businesswire.com: https://www.businesswire.com/news/home/20260813025520/en/ The articles, information, and content displayed on this webpage ...
Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% on Monday after the biotechnology company provided a positive regulatory update on its lead drug candidate, seralutinib, and announced it had regained ...
Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment MT Jul. 27 Gossamer Bio, Inc. Announces Proceeding Toward Planned NDA Subm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results